New prospects in the use of Kadcyla® in breast cancer

New prospects in the use of Kadcyla® in breast cancer

As is known, the HER-2-expressing biological subtype of breast cancer (BC) is characterized by an aggressive course and has a poorprognosis in the absence of specific treatment. Before the emergence of trastuzumab, 5-year overall survival in patients with the disseminated forms of BC was 20 % (media...

Full description

Bibliographic Details
Main Authors:	G. A. Dashyan, V. F. Semiglazov, P. V. Krivorot’ko, R. M. Paltuev, E. E. Topuzov, T. Yu. Semiglazova, E. K. Zhil’tsova, R. V. Donskikh, T. T. Tabagua, V. S. Apollonova
Format:	Article
Language:	Russian
Published:	ABV-press 2015-11-01
Series:	Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:	her-2-positve breast cancer metastatic breast cancer targeted therapy trastizumab t-dm1 transtuzumab emtansine kadcyla
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/458

Similar Items

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
by: G. A. Dashyan, et al.
Published: (2016-06-01)

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
by: Chung Young Kim, et al.
Published: (2019-08-01)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
by: Matthew N. Mills, et al.
Published: (2021-03-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives
by: Feiqi Liu, et al.
Published: (2020-09-01)

Antagonism Between Trastuzumab and Oncolytic VSV is Overcome by Conjugation to a Microtubule Destabilizer
by: Garcia, Vanessa
Published: (2015)

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
by: Mark Barok, et al.
Published: (2018-05-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary
by: Tommaso Giarratano, et al.
Published: (2018-12-01)

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
by: Heidi Egloff, et al.
Published: (2018-08-01)

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
by: Benjamin Daniels, et al.
Published: (2021-08-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer
by: T Yu Semiglazova, et al.
Published: (2015-03-01)

Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results)
by: L. G. Zhukova, et al.
Published: (2019-12-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
by: Patricia Miranda Romero, et al.
Published: (2015-02-01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
by: Elena López-Miranda, et al.
Published: (2020-11-01)

The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
by: V F Semiglazov, et al.
Published: (2013-12-01)

Future prospects for breast cancer immunotherapy
by: V. F. Semiglazov, et al.
Published: (2018-11-01)

Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)

Correlation of the value of sonoelastography strain ratio with the degree of pathological regression in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
by: E. A. Bus’ko, et al.
Published: (2017-02-01)

New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
by: T Yu Semiglazova, et al.
Published: (2016-06-01)

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
by: Takahiro Nakayama, et al.
Published: (2021-07-01)

CLINICAL CASE OF SUCCESFUL APPLICATION OF KADSYLA APPLICATION IN METASTATIC HER2 POSITIVE BREAST CANCER
by: D. D. Sakaeva
Published: (2017-11-01)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
by: Alexey A. Larionov
Published: (2018-04-01)

Immediate breast reconstruction using titanised mesh
by: P. V. Krivorotko, et al.
Published: (2020-11-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
by: Adam Sharp, et al.
Published: (2015-02-01)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
by: William Jacot, et al.
Published: (2019-11-01)

Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis
by: Hao Liao, et al.
Published: (2021-05-01)

Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01)

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
by: Lawrence H. Cheung, et al.
Published: (2019-07-01)

The role of digital mammography, scintimammography with <sup>99m </sup>Tc-methoxyisobutylisonitrile (MIBI) and ultrasound in the diagnosis of multicentric breast cancer
by: A. V. Chernaya, et al.
Published: (2020-03-01)

Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature
by: Zhang L, et al.
Published: (2017-11-01)

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
by: Zhang J, et al.
Published: (2017-11-01)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
by: Tejal A. Patel, et al.
Published: (2019-09-01)

Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer
by: T. Yu. Semiglazova, et al.
Published: (2014-07-01)

NEW ADVANCES IN THE TREATMENT OF BREAST CANCER: THE ROLE EPOTHILONES
by: T. Y. SEMIGLAZOVA, et al.
Published: (2017-06-01)

Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board
by: E V Artamonova, et al.
Published: (2014-06-01)

Cannot write session to /tmp/vufind_sessions/sess_tru47360ftiitgjcuvtmcbeldk